Alzheimer’s Drug Poses a Dilemma for the F.D.A.

By BY PAM BELLUCK AND REBECCA ROBBINS from NYT Health If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. https://ift.tt/3z8ZOEC